Now Recruiting in Cary, North Carolina:
Clinical Trial for Gout Treatment
Atom Therapeutics is pleased to announce that we are actively recruiting participants in the Cary, NC area for a clinical study evaluating our investigational therapy ABP-671 (lingdolinurad) in combination with allopurinol.
This study is focused on advancing treatment options for individuals living with chronic gout and acute gout, aiming to assess the safety, tolerability, and effectiveness of adding ABP-671 to standard allopurinol therapy.
Who may be eligible?
We are looking for adults aged 18-75 years of age, in and around Cary who:
• Have been diagnosed with gout or acute gout
• Are currently taking allopurinol
• Meet additional study criteria
Why participate?
• Access to investigational treatment options
• Study-related care at no cost
• Opportunity to contribute to the future of gout treatment
If you or someone you know in the Cary / Research Triangle area may be interested, we encourage you to reach out or learn more about participating.
Atom’s lead product, ABP-671, is in multicenter Phase 2b/3 clinical trials worldwide, including the US, for treatment of chronic gout and hyperuricemia. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs on the market.
Another small molecule, ABP-745 for acute gout, has demonstrated safety and efficacy in completed Phase 1 clinical trials in the US. ABP-745 is in Phase 2 clinical trials for acute gout and preparations are underway for Phase 2 clinical trials in other indications.